Sermorelin research: what the published studies show

Diagnostic Use

A 1999 review describes sermorelin as the shortest synthetic peptide with the full biological activity of GHRH.^[1]Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary.^[1]The review reports that hormone responses to 1 microgram per kilogram intravenously appear to be a rapid and relatively specific test for growth hormone deficiency.^[1]

Fewer children without the deficiency showed false positive responses after sermorelin than after other provocative tests.^[1]The review adds a limit that matters: a normal response cannot exclude growth hormone deficiency arising from a hypothalamic deficit.^[1] Confirming disease in those patients still requires a subnormal response to a different provocative test.^[1]

Growth Hormone Deficiency Studies

The same review reports that once-daily subcutaneous sermorelin at 30 micrograms per kilogram at bedtime is effective in some prepubertal children with idiopathic growth hormone deficiency.^[1] It calls the supporting data limited, and that word is the review's own.^[1]

Significant increases in height velocity were sustained through 12 months of treatment, and data in a few children suggest the effect held for 36 months.^[1] Catch-up growth was induced in the majority of deficient children.^[1] Slow-growing, shorter children with delayed bone and height age appeared to respond well.^[1] The review states that the effect of long-term treatment on final adult height was not established.^[1]

Growth Hormone Release in Rats

A 2005 study synthesized three maleimido derivatives of hGRF(1-29) and compared them against hGRF(1-29) itself in rats.^[2] The comparator arm is sermorelin, and the paper's subject compounds are derivatives of it.^[2]

All three albumin conjugates showed enhanced in vitro stability against dipeptidyl peptidase-IV and were bioactive in a GH secretion assay in cultured rat anterior pituitary cells.^[2] The best derivative, which the authors named CJC-1295, showed a four-fold increase in GH area under the curve over two hours compared with hGRF(1-29).^[2] That comparison is what establishes hGRF(1-29) as the shorter-acting of the pair, and the four-fold figure belongs to the derivative rather than to this product.^[2]

The Class in Human Studies

A 2018 review of growth hormone secretagogues in human subjects states that few long-term, rigorously controlled studies have examined their efficacy and safety.^[3] It reports that secretagogues might improve growth velocity in children, stimulate appetite, improve lean mass in wasting states, decrease bone turnover, increase fat-free mass and improve sleep.^[3] Every one of those is stated as a possibility, and the hedge is the review's own.^[3]

Available studies indicate the class is well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity.^[3] The review closes by saying the long-term safety of these compounds, including cancer incidence and mortality, still needs evaluation.^[3] It covers GHRH analogues and ghrelin receptor agonists together, so nothing in it is specific to this compound.^[3]

A 2026 narrative review of peptides in sports medicine names sermorelin among approved and unapproved compounds marketed direct to patients.^[4] It reports that many unapproved peptides show favorable outcomes in animal models while rigorous human safety data remain scarce.^[4] It also discusses the placebo effect as a mediator of perceived peptide efficacy.^[4]

State of the Evidence

Three things shape this page, and the first is that most of it is review.

Three of the four sources carry no primary data.^[3] The only experimental paper here uses this compound as a comparator while studying a derivative.^[2] The clinical claims all come from one 1999 review, which describes the underlying treatment data as limited.^[1]Reference 1 is a full clinical review of sermorelin's former use as a diagnostic and treatment agent.^[1]

The third is what the reviews say about themselves. The class review reports few long-term controlled studies and an open question on long-term safety.^[3] The 2026 review notes scarce human safety data for unapproved peptides generally.^[4]Neither of those is a finding against this compound, and neither is a finding for it.